In a groundbreaking collaboration, leading obesity and dietitian societies have unveiled a comprehensive consensus statement addressing the nuanced use of obesity pharmacotherapies, particularly incretin-based therapies (IBTs) such as glucagon-like peptide-1 (GLP-1) receptor agonists, which have revolutionized managing weight loss but also introduced complex nutritional, functional, and psychological considerations. Presented at the 2026 European Congress on Obesity (ECO) in Istanbul, this pivotal document reflects the concerted efforts of an international team led by Dr. Laurence Dobbie from King’s College London, aiming to optimize patient outcomes through integrated multidisciplinary strategies.
The advent of IBTs marks an unprecedented shift in obesity management paradigms. These agents operate by modulating incretin hormone pathways, influencing appetite regulation, insulin secretion, and glucose homeostasis. Despite their transformative impact on weight reduction, the therapies are not devoid of risks, necessitating refined clinical protocols to mitigate adverse effects and maximize therapeutic gains. As these medications become more widespread, healthcare providers face the formidable challenge of balancing efficacy with the maintenance of patients’ nutritional integrity and psychological well-being.
Central to the consensus is the role of medical nutritional therapy (MNT), a critical adjunct to pharmacotherapeutics. Delivered by registered dietitians, MNT encompasses tailored dietary guidance that ensures adequate protein, micronutrient, and vitamin intake—elements essential for preserving muscle mass and preventing malnutrition amid substantial weight loss. Moreover, dietitians play a crucial role in individualized dose-scaling of obesity drugs, attenuating gastrointestinal side effects such as nausea and vomiting, which are common barriers to adherence. Importantly, the consensus emphasizes the delivery of MNT within a framework of weight-inclusive and empowering communication, recognizing that health transcends mere numerical values on the scale.
The intersection of obesity treatment and mental health forms another pillar of this comprehensive statement. While IBTs have been associated with improved psychological outcomes, patients often enter treatment with pre-existing vulnerabilities including anxiety, depression, or eating disorders. The document calls for vigilant mental health screening and monitoring by multidisciplinary teams, integrating psychological expertise to identify and address the re-emergence or exacerbation of mental health issues during the transformative process of significant weight loss. Special attention is drawn to screening for alcohol use disorders prior to GLP-1 therapy initiation due to potential pharmacodynamic interactions.
Clinicians are urged to adopt more sophisticated monitoring beyond traditional metrics such as body mass index (BMI). Emerging evidence highlights that approximately 24-30% of weight lost via IBTs corresponds to fat-free mass, predominantly muscle tissue, which may have profound implications for physical function and metabolic health, especially in older adults at heightened risk for sarcopenia. The consensus proposes a pragmatic target of an approximate 3:1 ratio favoring fat loss over lean mass depletion. To facilitate this, advanced body composition assessments, including dual-energy X-ray absorptiometry (DXA) and bioelectrical impedance analysis (BIA), alongside functional measures like handgrip strength and sit-to-stand tests, are recommended where resources permit, reinforcing the shift toward personalized and functionally oriented evaluations.
The profound importance of physical activity is underscored, with a dual focus on aerobic exercise to augment weight loss and resistance training to preserve muscular integrity. These physical interventions synergize with IBTs and MNT, preventing excessive lean mass loss while simultaneously enhancing metabolic and psychological health. The consensus highlights the necessity of patient education to foster sustainable engagement in physical activity as an integral component of obesity care pathways.
Addressing the socioeconomic disparities that permeate obesity treatment access surfaces as a critical concern. Minority ethnic communities and socioeconomically disadvantaged groups disproportionately bear the burden of obesity yet often encounter substantial barriers, including limited access to IBTs and specialist nutritional services. The consensus highlights the pernicious effects of prescription regulations favoring patients with obesity-related complications over those without, perpetuating stigma and impeding early intervention strategies. It advocates for policy reforms to expand coverage for obesity pharmacotherapies and for healthcare systems to bolster equitable access to dietitian-led MNT, potentially narrowing health disparities and improving adherence and clinical outcomes.
Despite the transformative potential of IBTs, the authors illuminate significant lacunae in research, particularly concerning the long-term nutritional, functional, and psychological impacts of these treatments. A systematic review of 417 randomized controlled trials revealed that nutritional intake and biomarker reporting are sparse, with fewer than 5% assessing bone health, micronutrient status, or physical function. Such gaps hinder comprehensive safety profiling and limit evidence-based guidelines.
To address these deficiencies, the consensus delineates an ambitious research agenda. Priorities include establishing core outcome sets for IBT trials to standardize reporting; developing malnutrition screening tools tailored to obesity contexts; rigorous evaluation of muscle function and performance metrics; and investigating optimal protein intake protocols to safeguard lean tissue during therapy. Psychological outcomes require dedicated attention, alongside innovations in dose titration to reduce gastrointestinal side effect-induced discontinuations. Pharmacokinetic safety assessments and mixed-methods studies capturing real-world patient experiences, including post-cessation and post-bariatric surgery contexts, are also urgently needed.
In concluding, the statement proclaims IBTs as emblematic of a paradigm shift in obesity treatment, necessitating the integration of dietitian-led MNT with psychological and functional support frameworks. Key therapeutic goals revolve around mitigating gastrointestinal adverse effects, preempting micronutrient deficiencies, and preserving lean mass through nutrient-dense diets enriched in protein, fiber, and fluids, complemented by targeted supplementation and resistance exercise. Emphasis is placed on holistic care that attends to identity transformation, coping mechanisms, and potential disordered-eating patterns, all grounded in respectful and inclusive patient engagement.
As obesity emerges increasingly recognized as a chronic disease requiring multifaceted management, this consensus represents a seminal step toward harmonizing pharmacological advances with nutritional science, psychological insight, and functional rehabilitation. The future of obesity care hinges on such integrative approaches, driven by patient-centered research and equitable healthcare delivery systems that transcend stigma and structural barriers.
Subject of Research: Use of incretin-based therapies in obesity treatment and associated nutritional, functional, and psychological considerations.
Article Title: New Consensus on Optimizing Obesity Drug Use Emphasizes Nutrition, Mental Health, and Functional Support
News Publication Date: 2026 (at European Congress on Obesity)
Web References: Not provided
References: Not provided
Image Credits: Not provided
Keywords: Obesity treatment, incretin-based therapies, GLP-1 receptor agonists, medical nutritional therapy, body composition, muscle mass preservation, psychological health, physical activity, socioeconomic disparities, obesity pharmacotherapy, consensus statement
Tags: dietitian role in obesity drug useEuropean Congress on Obesity 2026 highlightsGLP-1 receptor agonists in weight managementincretin-based therapies for obesityintegrated obesity care modelsmanaging side effects of obesity medicationsmedical nutritional therapy for obesitymultidisciplinary obesity treatment strategiesnutritional considerations in obesity pharmacotherapyobesity pharmacotherapy guidelines 2026optimizing patient outcomes in obesity treatmentpsychological impact of incretin drugs
